Xspray Pharma AB (publ) (FRA:6XP)

Market Cap	43.68M -55.2%
Revenue (ttm)	222.71K
Net Income	-14.40M
EPS	-0.34
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	215
Open	0.8800
Previous Close	0.9010
Day's Range	0.8800 - 0.8980
52-Week Range	0.7760 - 3.1350
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 4, 2026

About Xspray Pharma AB

Xspray Pharma AB (publ), a pharmaceutical company, engages in the development of protein kinase inhibitors for targeted cancer treatments in Sweden. The company develops Dasynoc, an amorphous version of dasatinib for the treatment of chronic myeloid leukemia (CML)and acute lymphoblastic leukemia; XS003, an amorphous non-crystalline nilotinib for the treatment of CML; XS008, an axitinib for the treatment of kidney cancer; and XS025, a amorphous non-crystalline cabozantinib for the treatment of renal cell carcinoma and other cancers. It has partn...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2003
• Employees: 24
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 6XP

Financial Performance

Financial numbers in SEK

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Oct 26, 2026

Data Sources Report a data error